Skip to main content
main-content
Top

09-16-2017 | Sexual dysfunction | Practical approach | Article

A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes

Journal: Diabetes Therapy

Authors: Charmaine Rochester-Eyeguokan, Lisa Meade

Publisher: Springer Healthcare

share
SHARE

Abstract

Female sexual dysfunction (FSD) is highly prevalent in women with diabetes mellitus (DM), yet it remains unaddressed, undiagnosed, and untreated. Hypoactive sexual desire disorder (HSDD) is the most common complaint among women with FSD, but there is a paucity of research into its multifactorial etiology. Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women. Women with DM diagnosed with HSDD may require a multidisciplinary approach for optimal management.
Literature
1.
Enzlin P, Rosen R, Wiegel M, et al. Sexual dysfunction in women with type 1 diabetes. Diabetes Care. 2009;32:780–5. CrossRefPubMedPubMedCentral
2.
Doruk H, Akbay E, Cayan S, et al. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl. 2005;51:1–6. CrossRefPubMed
3.
Enzlin P, Mathieu C, Van den Bruel A, et al. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care. 2003;26:409–14. CrossRefPubMed
4.
Mimoun S, Wylie K. Female sexual dysfunctions: definitions and classification. Mauritas. 2009;63:116–8.
5.
Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010;110:7–11. CrossRefPubMed
6.
Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114–28. CrossRefPubMed
7.
Kingsberg SA, Iglesia CB, Kellogg S, et al. Handbook on female sexual health and wellness. Association of Reproductive Health Professionals. http://​www.​arhp.​org/​Publications-and-Resources/​Clinical-Practice-Tools/​Handbook-On-Female-Sexual-Health-And-Wellness ARHP 2011:1–24. Accessed 31 Aug 2017.
8.
Miocic J, Car N, Metelko Z. Sexual dysfunction in women with diabetes mellitus. Diabetologia Croatica. 2008;37:35–42.
9.
Palacios S, Casta R, Grazziotin A. Epidemiology of female sexual dysfunction. Mauritas. 2009;63:119–23.
10.
Buster JE. Managing female sexual dysfunction. Fertil Steril. 2013;100:905–15. CrossRefPubMed
11.
Clayton AH, Goldfischer ER, Goldstein I, et al. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6:730–8. CrossRefPubMed
12.
US FDA. FDA approves first treatment for sexual desire. https://​www.​fda.​gov/​newsevents/​newsroom/​pressannouncemen​ts/​ucm458734.​htm. Accessed 19 June 2017.
13.
Katz M, Derogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15. CrossRefPubMed
14.
Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder results from a randomized withdrawal trial. J Sex Med. 2011;8:3160–72. CrossRefPubMed
15.
Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women, a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62. CrossRefPubMed
16.
Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38–53. CrossRefPubMed
17.
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3489–510. CrossRefPubMed
18.
Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communication with patients on sexual health. Pharmacotherapy. 2013;33(4):411–21. CrossRefPubMed
19.
Safarinejad MR, Hosseini SY, Asgari MA, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106:832–9. CrossRefPubMed

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.